I-InnoCare Pharma, inkampani ekhokelayo kwi-biopharmaceutical, ibhengeze namhlanje ukuba isigulana sokuqala sithotyiwe kwiSigaba sesi-II solingo lwezonyango lwe-Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib kunyango lwe-immune immune thrombocytopenia (ITP) eTshayina.
I-immune immune thrombocytopenia (ITP), ekwabizwa ngokuba yi-idiopathic thrombocytopenic purpura, sisifo esifunyenweyo sokhuselo lomzimba oluphawulwa kukuncipha kwezibalo zeplatelet zegazi, okukhokelela ekonyukeni komngcipheko wokugruzuka nokopha[i]. I-pathogenesis ephambili ye-ITP kukulahlekelwa ukunyamezela komzimba kwi-platelet auto-antigens. Oku kunyamezelwa kwe-immune kukhokelela ekutshatyalalisweni kweplatelet kunye nokuncipha kwemveliso yeplatelet ukusuka kwi-megakaryocytes ngama-autoantibodies kunye ne-cytotoxic T lymphocytes.
Kuphela malunga ne-70% yezigulane ezisabelayo kunyango lodidi lokuqala, ezinye izigulane zisaxhathisa okanye zibuyele emva konyango oludibeneyo, ngoko ke kuyimfuneko ukuhlola iithagethi zonyango olutsha. Ukuvinjelwa kwe-BTK kunokunciphisa ukutshatyalaliswa kweplatelet ngokuthintela ukusebenza kweeseli ze-B kunye nokuveliswa kwe-autoantibody.
Izehlo zonyaka ze-ITP kubantu abadala zimalunga ne-2-10 iimeko ezintsha kubantu abayi-100,000[ii],[iii]. Abantu abadala abangaphezu kweminyaka engama-60 ubudala basengozini enkulu ye-ITP, kwaye abafazi bokuzala banomngcipheko ophezulu kunamadoda akwiqela elifanayo.
UDkt Jasmine Cui, umseki-ntsapho, uSihlalo kunye ne-CEO ye-InnoCare uthe, "Akukho inhibitor ye-BTK evunyiweyo yonyango lwezigulane ezine-ITP kwihlabathi. I-BTK yi-kinase ephambili kwindlela yokubonisa i-cell receptor ye-B, eyimfuneko ekusebenzeni kwe-B lymphocytes, i-macrophages kunye nezinye iiseli zokuzivikela kunye nokuveliswa kwe-antibodies kwinkqubo ye-pathological ye-ITP. I-Orelabrutinib inokukhethwa okuphezulu okujoliswe kuko kunye neprofayili yokhuseleko, ekulindeleke ukuba izise iindlela zonyango ezinovelwano kwizigulana ze-ITP. "
INTO ONOKUYITHATHA KWELI NQAKU:
- I-BTK yi-kinase ephambili kwindlela yokubonisa i-cell receptor ye-B, eyimfuneko ekusebenzeni kwe-B lymphocytes, i-macrophages kunye nezinye iiseli zokuzivikela kunye nokuveliswa kwe-antibodies kwinkqubo ye-pathological ye-ITP.
- I-immune immune thrombocytopenia (ITP), ekwabizwa ngokuba yi-idiopathic thrombocytopenic purpura, sisifo esifunyenweyo sokhuselo lomzimba oluphawulwa kukuhla kwi-peripheral platelet counts, okukhokelela ekonyukeni komngcipheko wokugruzuka nokopha[i].
- UJasmine Cui, umseki-ntsapho, uSihlalo kunye ne-CEO ye-InnoCare uthe, "Akukho inhibitor ye-BTK evunyiweyo kunyango lwezigulane ezine-ITP emhlabeni.